Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Not a single study

Story checked

The First-Ever Reverse-Aging Treatment Has Been Injected Into a Human - Business Insider (opens in a new tab)

businessinsider.com · 2026-06-09

Short answerEvidenceSource

Short answer

Not a single study

No clear answer.

The article covers a research area rather than reporting a specific new paper, so there is no single study to check it against.

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

This story isn't reporting one study.

The article covers a research area rather than reporting a specific new paper, so there is no single study to check it against.

Open claim evidence
3

Search result

No single source study.

The article covers a research area rather than reporting a specific new paper, so there is no single study to check it against.

Related research

Research nearby

Research on this topic

Nearby papers when the source is unclear.

and 11 more considered

Then inspect each claim

Evidence layer

Claim by claim

What the story asserts. With no source study, there is nothing to check these against.

Claim 1 of 6Not checkedA first-of-its-kind shot that promises to reverse aging was just injected into a human body.View evidenceHide evidence

As statedfirst-of-its-kind

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 2 of 6Not checkedThe company said its first patient has been dosed with a cellular reprogramming injection designed to reverse age-related diseases.View evidenceHide evidence

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 3 of 6Not checkedThe injection went into one eyeball of a single person with glaucoma, and scientists will watch for how well it works and for safety issues over the next six months.View evidenceHide evidence

As stateda single person

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 4 of 6Not checkedThe story says Life Biosciences is the first to test this approach in humans, with a little under 20 patients slated to participate in the initial FDA trial of ER-100.View evidenceHide evidence

As stateda little under 20 patients

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 5 of 6Not checkedThe article says the therapy is controlled with a doxycycline-based on/off switch and uses three of the four Yamanaka factors, skipping the one most closely associated with cancer development.View evidenceHide evidence

As statedthree of the four Yamanaka factors

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 6 of 6Not checkedThe article notes that a major concern is cancer, because two of the four Yamanaka factors are oncogenes and mouse studies have reported tumors.View evidenceHide evidence

As statedtwo of the four

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Finally, the search trail

Method layer

No single source study was found.

NewsLink still surfaces nearby research so you can inspect the field instead of a single paper.

Nearby research

No exact source, but these papers are close.

PubMed, Crossref, Europe PMC · 15 candidate papers

Candidate

Glaucoma Research Community and FDA Look to the Future, II: NEI/FDA Glaucoma Clinical Trial Design and Endpoints Symposium: Measures of Structural Change and Visual Function

Investigative Opthalmology & Visual Science · 2011 · Crossref

Tessa (opens in a new tab)Source (opens in a new tab)

And 10 more candidates considered.